by Robert S. Miller, MD. Dr. Nathan Pennell discusses some of the interesting obstacles he encountered when trying to prescribe crizotinib for 3 patients with ALK positive non-small cell lung cancer in the first few weeks following FDA approval in 2011.
Oct 20
Advance Care Planning: How Can We Improve Access and Uptake?
Dr. Chino welcomes Dr. Yael Schenker to discuss a new clinical trial testing the best way of engaging patients with Advance Care Planning (ACP), the process of understanding personal values, life goals, and medical care preferences so that patient wishes are honored at end-of-lif ... Show More
21m 30s
Jan 2014
E-cigs; PPI feedback; Be assertive with your doctor; Prostate cancer diagnosis
As the government calls for a ban on the sale of e cigarettes to under 18s, Dr Mark Porter is joined by Martin McKee, Gerard Hastings and Robert West to discuss who is using them and how they are being advertised. The chairman of NICE, David Haslam has suggested patients should d ... Show More
28m 3s
May 2022
Patient-Reported Outcomes in Clinical Trials
<p>JAMA Associate Editor Ethan Basch, MD, and Melanie Calvert, PhD, from the University of Birmingham, UK, discuss barriers to and strategies for including rigorous patient-reported outcomes in clinical trials, and reflect on Dr Calvert's recent JAMA paper on related ethical impl ... Show More
14m 26s
Aug 2018
Eric Ketcham, MD and Kathryn Hawk, MD – MAT 3-Rule
On today’s ACEP Frontline, Dr. Ryan Stanton discusses the MAT 3-Rule for prescribing buprenorphine for the opioid use disorder patient. Recorded live at LAC18, ACEP experts Dr. Eric Ketcham and Dr. Kathryn Hawk talk about how helping the patient with opioid withdrawal symptoms, t ... Show More
25 m
Jul 2023
Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Host: Harry Paul Erba, MD, PhD Guest: Courtney DiNardo, MD Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss ... Show More
23m 30s
Oct 2023
#341: What NOT to say to FDA
Description:Dive into the enlightening world of FDA inspections with Etienne Nichols and Mike Drues. In this comprehensive episode, the duo decodes the essence of effective communication, the importance of managing expectations, and the art of proactive dialogue with the FDA. The ... Show More
49m 11s